COVIRIX Medical
COVIRIX Medical is an Australian clinical-stage pharmaceutical company developing inhaled iminosugar antiviral compounds (lead CVX-20733) targeting respiratory viruses, with a direct-to-government sales model and an HKSE Chapter 18A IPO pathway.
- Company typePrivate
- Founded2020
- HeadquartersBentleigh East, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What COVIRIX Medical does
COVIRIX Medical is an Australian clinical-stage pharmaceutical company incorporated in March 2020 that develops repurposed iminosugar glucosidase inhibitor compounds—CVX-20733, CVX-20755, CVX-20788, and CVX-20700—administered via oral inhalation and intranasal routes as dry powder inhalers or nebulizers. The compounds target human host-cell alpha-glucosidase, interfering with viral entry and glycoprotein maturation, which the company claims confers broad-spectrum activity against SARS-CoV-2 (including Alpha, Beta, Delta, and Omicron variants), seasonal and avian influenza, and RSV, with reported EC50 values as low as 0.1 ug/mL in human respiratory cells. The company is concurrently developing an inhaled non-steroidal anti-inflammatory for Long-COVID syndrome and inflammatory pulmonary conditions such as asthma, COPD, and Interstitial Lung Disease.
The company's revenue model is built on direct-to-government pharmaceutical sales for pandemic preparedness and stockpiling, with planned wholesale pricing of US$250 per COVID treatment course and US$65 per broader respiratory treatment course—against production costs of US$15 and US$20 respectively. COVIRIX intends to leverage the CEO's clinical and regulatory relationships in India for its first commercial market, an NDA with a major European API manufacturer for global production, and a March 2026 Letter of Intent with Aptar Pharma for dry powder inhalation device technology. The only operating revenue stream today is AU/NZ distribution of DiaCarta COVID-19 PCR and rapid antigen test kits. The company is pre-revenue on its antiviral pipeline (Phase 1+2 trials planned) and is pursuing an HKSE Chapter 18A Biotech listing with a US$75 million IPO target at a US$4 share price, implying a US$419 million post-money valuation.
COVIRIX Medical firmographics
Firmographics- Name
- COVIRIX Medical
- Legal name
- COVIRIX Medical Pty Ltd
- Website
- https://covirix.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- COVIRIX Medical is an Australian clinical-stage pharmaceutical company developing inhaled iminosugar antiviral compounds (lead CVX-20733) targeting respiratory viruses, with a direct-to-government sales model and an HKSE Chapter 18A IPO pathway.
- Ownership category
- akta.pro rank
COVIRIX Medical industry classification
Industry- Product category
- Antiviral Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industries
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where COVIRIX Medical is headquartered
LocationHeadquarters
- HQ city
- Bentleigh East
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
COVIRIX Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Inhaled Antiviral Drug Sales: COVIRIX plans to generate revenue through direct sales of its inhaled antiviral drug (CVX-20733) to governments worldwide. The product is priced at US$250 per course for COVID treatment (approximately 1/3 to 1/6 the price of Pfizer's Paxlovid at US$700-$1,400 per course) and US$65 per course for broader respiratory treatment. The company assumes the current pharmaceutical sales practice of direct-to-government sales will continue. Production cost per course is estimated at US$15 (COVID) and US$20 (respiratory), including drug compound, packaging, and inhaler device.
- DiaCarta COVID Test Kit Distribution: COVIRIX Medical serves as Australia and New Zealand agent for distributing DiaCarta Rapid Antigen Test and PCR test kits, appointed by Metropolis Holdings (Hong Kong) Limited. This represents a distribution/reseller revenue stream for COVID diagnostic products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | COVID-19 Antiviral Treatment Course |
| Unit Pricing | Pay-as-you-go | Respiratory Treatment Antiviral Course |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
COVIRIX Medical product offering
Product offeringCore offering
COVIRIX Medical develops and plans to commercialize a portfolio of repurposed iminosugar glucosidase inhibitor compounds (CVX-20733, CVX-20755, CVX-20788, CVX-20700) delivered via oral inhalation and intranasal routes as broad-spectrum antiviral and anti-inflammatory therapeutics targeting SARS-CoV-2, influenza, RSV and other respiratory viruses. The company also distributes DiaCarta COVID-19 PCR and Rapid Antigen test kits in Australia and New Zealand as a Metropolis Holdings (Hong Kong) appointed agent.
Product overview
COVIRIX Medical is a pharmaceutical company developing a portfolio of antiviral and anti-inflammatory drug candidates delivered via inhalation for treatment and prophylaxis of respiratory viruses. The core products are glucosidase inhibitor compounds (CVX-20733, CVX-20755, CVX-20788, CVX-20700) administered as dry powder inhalers or nebulizers targeting pandemic-potential respiratory viruses including SARS-CoV-2, influenza, and RSV. The company also distributes DiaCarta COVID-19 diagnostic test kits (PCR and Rapid Antigen tests) and is developing an inhaled non-steroidal anti-inflammatory for Long-COVID and inflammatory pulmonary conditions.
Differentiator
Problem solved
Functional benefit
Brands
- DiaCarta Covid Test Kits: COVIRIX Medical appointed Australia and New Zealand agent for distributing DiaCarta Rapid Antigen Test and PCR test kits.
Products and services
- CVX-20733 Lead antiviral compound from the glucosidase inhibitor class targeting host molecular mechanisms used by respiratory viruses including SARS-CoV-2 and its variants. Administered via oral inhalation and intranasal routes as a dry powder inhaler or nebulizer. Lead candidate for COVID-19 antiviral treatment course priced at US$250 per course ex-factory gate.
- CVX-20755 Antiviral compound from the glucosidase inhibitor class targeting the same host molecular target as CVX-20733, interfering with viral entry and glycoprotein maturation during viral replication. Part of the broader portfolio of 11 molecules.
- CVX-20788
- CVX-20700
- DiaCarta QuantiVirus SARS-CoV-2 Multiplex PCR Test Kit
- DiaCarta QuantiVirus SARS-CoV-2 Antigen Rapid Home Test
Quantifiable outcome
- EC50 = 19 ug/mL against SARS-CoV-2 South African (Beta) variant in Vero cells; single digit EC50 values (e.g., 0.1 ug/mL) against Alpha, Beta, and parental strain in human respiratory cells; approximately 10x more potency in human respiratory cells demonstrated by Walter and Eliza Hall Institute, Melbourne
- +1 more outcomes
Companies that use COVIRIX Medical
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
COVIRIX Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
COVIRIX Medical partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Aptar PharmacoreTechnical collaboration under Letter of Intent to adapt Aptar's proprietary dry powder inhalation platform (Orbital DPI technology) for delivering COVIRIX Medical's broad-spectrum antiviral compounds. The collaboration leverages Aptar's dry powder inhalation platform and Nanopharm's formulation development services to conduct feasibility studies for an inhaled antiviral product targeting pandemic-potential respiratory viruses including COVID-19, influenza, and RSV. If successful, the project intends to explore development of an integrated finished product for global public health applications.
- NewGenIvfminorNewGenIvf signed non-binding term sheet for potential reverse merger with COVIRIX in June 2024. Update on potential reverse merger provided in July 2024. This represents a potential corporate restructuring or listing pathway rather than a product partnership.
- Asian Pharmaceuticals Pvt LtdcoreGMP Manufacturer for clinical trials in Nepal. Provides manufacturing capabilities for nebulized formulation of CVX 20733.
- Numolux GroupcoreNumolux-COVIRIX Medical Partnership announced in August 2023 for potential collaboration in the African market for COVID-19 treatment and pandemic preparedness.
- Medical Ventures Pvt LtdcoreMOU with Medical Ventures Pvt Ltd for CRO support for clinical trials in Nepal. Supports acceleration of Re-Phase I, Dose escalation Phase I, and Phase II studies.
- DiaCarta InccoreCOVIRIX Medical appointed as Australia and New Zealand agent by Metropolis Holdings (Hong Kong) Limited for distributing DiaCarta Rapid Antigen Test and PCR test kits. DiaCarta COVID-19 tests rank top 3 among FDA SARS-CoV-2 Reference Panel Tests and are approved by US FDA for emergency use. This partnership was elevated from local to global level in June 2022.
- Major European API & Pharmaceutical CompanycoreNDA signed with major European API & pharmaceutical company with global production/distribution chain. The company has unique expertise in inhaled drug delivery devices and substantial FDA-approved production capacity of GMP standard for producing Active Pharmaceutical Ingredients for global markets.
- ViroClinics, NetherlandscoreRevalidation tests of CVX 20733, CVX 20755, and CVX 20788 antiviral activity against UK and South African variants of SARS-CoV-2 conducted at ViroClinics, Netherlands. Lead compound CVX-20733 activity against SARS-CoV-2 verified with EC50 = 19 ug/mL against South African (Beta) variant.
- Walter and Eliza Hall Institute (WEHI)coreCompleted virology test data sharing agreement with WEHI on CVX 20733, CVX 20755 compounds. WEHI demonstrated compounds are approximately 10x more potent in human respiratory cells compared to Vero cells.
- Southern Research (SR) Laboratories, USAcoreAntiviral studies against SARS-CoV-2 conducted at Southern Research Laboratories, USA in November 2020. Initial market intelligence of preliminary antiviral efficacy for 20755 and 20788 obtained from SR Laboratories.
- Deakin UniversitycoreService engagement of Prof David Morton as Consultant Aerosol Scientist from Deakin University, Melbourne. Prof Morton provides expertise in aerosol science and inhaled drug delivery development.
- COVID Pharmaceutical Pty LtdcoreMOU with COVID Pharmaceutical Pty Ltd for license to develop and repurpose CVX 20733 and related compounds for both anti-viral and anti-inflammatory therapies.
- Baruch S. Blumberg InstitutecoreScientific Technical Advisory Board member Dr Timothy Block is President of the Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center and Hepatitis B Foundation. Collaborative studies planned to explore: (i) Reducing mutation rate of SARS-CoV-2 virus (ii) synergy benefit of combining COVIRIX compounds with other available antivirals (iii) developing novel pro-drugs of COVIRIX compound class.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
COVIRIX Medical competitors and assessment
Company assessmentDirect peers
- Pulmatrix: Clinical-stage biopharma developing inhaled therapeutics for respiratory diseases including pulmonology and infectious disease applications. Direct peer in the inhaled respiratory therapeutics category with a similar product development profile targeting respiratory virus infections.
- Aerogen: Medical device company specializing in nebulized drug delivery technology for respiratory therapeutics in hospital and outpatient settings. Direct peer in the inhaled respiratory drug delivery space, having partnered with Gilead on inhaled Remdesivir development.
Emerging players
- Atea Pharmaceuticals: Clinical-stage biopharma developing oral antivirals including bemnifosbuvir (AT-527) for COVID-19 and other RNA viruses. Comparable to COVIRIX in pursuing antiviral development for pandemic respiratory viruses, though using direct-acting antiviral approach rather than host-targeting.
- Arcturus Therapeutics: Clinical-stage biotech developing inhaled mRNA vaccine and therapeutic platforms for COVID-19 and other respiratory viruses. Closely comparable to COVIRIX's inhaled respiratory virus therapeutic approach, with a parallel focus on needle-free respiratory virus interventions.
- Romark Laboratories: Pharmaceutical company developing Alinia (nitazoxanide), a repurposed broad-spectrum antiviral with activity against COVID-19, influenza, and other respiratory viruses. Closely comparable to COVIRIX's strategy of repurposing existing molecules as broad-spectrum antivirals for respiratory infections.
Broad incumbents
- Gilead Sciences: Biopharmaceutical company with Veklury (Remdesivir), the first approved COVID-19 antiviral. Most directly comparable to COVIRIX on the inhaled delivery dimension, having collaborated with Aerogen on inhaled Remdesivir development to target respiratory tract infections.
- Merck & Co. Major pharmaceutical company with Molnupiravir (Lagevrio) oral COVID-19 antiviral. Competes with COVIRIX in the COVID antiviral treatment market, offering comparable global manufacturing scale and existing procurement relationships with governments.
- Pfizer: Major global pharmaceutical company with Paxlovid (nirmatrelvir/ritonavir), the leading oral COVID-19 antiviral. Directly competes with COVIRIX for government and institutional COVID antiviral procurement with established global manufacturing, distribution, and regulatory relationships.
- Shionogi: Japanese pharmaceutical company with Xocova (ensitrelvir), an oral COVID-19 antiviral approved in Japan. Comparable to COVIRIX in developing COVID-19 antiviral treatments, though a much larger established pharma with broader portfolio.
Others
- Vectura: Drug delivery company specializing in inhaled drug development for respiratory diseases (now part of Philip Morris). Functions as an adjacent ecosystem enabler comparable to Aptar Pharma in COVIRIX's supply chain for inhaled respiratory drug delivery platforms and devices.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
COVIRIX Medical social profiles
Digital presenceCOVIRIX Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
COVIRIX Medical leadership team
Management profileNumber of profiles
Profiles7 records
COVIRIX Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
COVIRIX Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about COVIRIX Medical
What does COVIRIX Medical do?
COVIRIX Medical develops and plans to commercialize a portfolio of repurposed iminosugar glucosidase inhibitor compounds (CVX-20733, CVX-20755, CVX-20788, CVX-20700) delivered via oral inhalation and intranasal routes as broad-spectrum antiviral and anti-inflammatory therapeutics targeting SARS-CoV-2, influenza, RSV and other respiratory viruses. The company also distributes DiaCarta COVID-19 PCR and Rapid Antigen test kits in Australia and New Zealand as a Metropolis Holdings (Hong Kong) appointed agent.
Is COVIRIX Medical a public or private company?
COVIRIX Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was COVIRIX Medical founded?
COVIRIX Medical was founded in 2020. It employs 1 to 10 people.
Where is COVIRIX Medical based?
COVIRIX Medical is headquartered in Bentleigh East, Australia, in the Oceania region.
How does COVIRIX Medical make money?
Two revenue lines are on record. Inhaled Antiviral Drug Sales are the primary driver. The others are diaCarta COVID Test Kit Distribution.
Who are COVIRIX Medical's main competitors?
Direct peers on record are Pulmatrix and Aerogen. Emerging players are Atea Pharmaceuticals, Arcturus Therapeutics and Romark Laboratories. Broad incumbents are Gilead Sciences, Merck & Co., Pfizer and Shionogi. Vectura is listed as an others.
Does COVIRIX Medical have an API?
No public API is recorded for COVIRIX Medical.
What industry is COVIRIX Medical in?
COVIRIX Medical's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.